Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in the overweight population, generating significant burden on hepatology clinics and liver transplant centers. 1, 2 NAFLD spans a spectrum of disease, from benign hepatic triglyceride accumulation (steatosis) to non-alcoholic steatohepatitis, 3 and appears to be a precursor to type 2 diabetes (T2DM). Abdominal obesity, insulin resistance (IR) and dyslipidemia are correlated with a greater incidence of NAFLD, also independently associated with an increased risk of cardiovascular events and chronic kidney disease. 4 There are currently no accepted pharmacological therapies for NAFLD. 5 Weight loss of 7 to 10% of body weight through lifestyle modification has shown the most success to date. 6, 7 Weight-loss and permanent maintenance of weight lost remain however unrelenting clinical challenges. 8 IR appears necessary in the development of NAFLD 9 . IR can result from adipocytes altered cytokine secretion impairing insulin signaling, and lipotoxicity from ectopic fat deposition. 10 Nutrientpoor and energy-dense substrate abundance increases mitochondrial and peroxisomal workload, resulting in increased free radicals production, depleted antioxidant defense, and perpetuating IR further via systemic inflammation activation. 11, 12 Bioactive food-constituents propose new treatment approaches in the modulation of inflammation and oxidative-stress. 13 The clinical investigation of vitamin E and polyunsaturated fatty acids provides insights into how increased exposure to bioactive food-constituents may have benefits in NAFLD, even in the absence of weight loss. 14 Resveratrol is such compound. The polyphenol is found in grapes, berries, peanuts, and certain therapeutic plants. 15 Dietary consumption is typically in micrograms. 16 Resveratrol's pleiotropic potential has been explored extensively over the last three decades in models of adipogenesis, inflammation, oxidative-stress, insulin resistance, cancer chemoprevention, and age-related degeneration. 17 Resveratrol's potential role in obesity-related complications lies in the purported calorie-restriction mimicking, 18, 19 via activation of key regulators of metabolic health, namely AMPactivated kinase (AMPK), nuclear factor (erythroid-derived)-like 2 (Nrf2), and nicotinamide adenine dinucleotide NAD + -dependent deacetylase (SIRT1). 20 Pre-clinical studies have demonstrated a M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 preventive role of resveratrol in diet-induced NAFLD. Animals fed high-energy diets with resveratrol still gained weight, but hepatic steatosis, IR and systemic inflammation were significantly prevented. [21] [22] [23] [24] Resveratrol activated AMPK and SIRT1 in hepatic and muscle tissue, regulated inflammatory cytokines, increased antioxidant capacity, insulin sensitivity, and reduced hepatic denovo lipogenesis compared to control regimen. Furthermore, the observed effects on gene expression in muscle, hepatic and adipose tissue postulated a potential for a sustained therapeutic effect in presence of established dysregulation. No dose-therapeutic effect relationship in-vivo data is currently available, but observation of extensive enteral metabolism suggests that large doses are required to obtain parent resveratrol concentration matching in-vitro concentrations likely to demonstrate efficacy. 25 Initial clinical investigations in obesity have provided variable results, likely explained by the heterogeneity in dosages, subjects' baseline health status, and investigation protocols assessing either chronic or acute effects. [26] [27] [28] [29] [30] [31] To-date, the therapeutic efficacy of resveratrol in established clinical NAFLD has not been investigated.
We hypothesized that in overweight or obese men with NAFLD, 3000 mg daily resveratrol over 8 weeks would i) improve hepatic and metabolic dysregulation with insulin resistance as primary outcome, assessed by the euglycemic-hyperinsulinemic clamp; and ii) be safe, and result in high parent resveratrol concentration.
METHODS

Study design and participants
This randomized, double-blind, placebo controlled trial was approved by the Human Research Ethics Committees of the Princess Alexandra Hospital and the University of Queensland, Brisbane, Australia. Twenty men with body mass index above 25kg/m 2 and waist circumference above 90cm were recruited prospectively from hepatology outpatient clinics in 2011 and 2012. The primary inclusion criterion was evidence of hepatic steatosis on ultrasound. Exclusion criteria were any known causes of steatosis: viral hepatitis, daily ethanol consumption above 40g, or use of steatogenic medications. Patients with evidence of cirrhosis, T2DM, history of chronic kidney M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 disease and serious cardiovascular disorders were also excluded. After screening by the primary investigator (PI) and providing informed written consent, volunteers were allocated to either resveratrol or placebo by computer-generated randomization. Participants underwent baseline measures. Dosing involved three capsules (500mg each) of resveratrol or placebo before breakfast, and another three of the same capsules before bedtime, equating to 3000mg resveratrol daily in the treatment arm. Resveratrol (from Polygonum Cuspidatum) was purchased from Biotivia Bioceuticals, and placebo was identically presented microcellulose filled capsules. Participants were instructed to maintain usual dietary intake and physical activity throughout the study. All baseline measures were repeated after 8 weeks. Participants and investigating staff were blinded to the randomization until completion of results analyses. Pharmacokinetics and target genes transcription were analyzed post un-blinding. All co-authors had access to the study data, reviewed and approved the final manuscript.
Safety monitoring and compliance
Subjects were reviewed weekly by the PI to assess adverse events. A clinical pharmacologist independent to the study reviewed the weekly liver and kidney function biochemistry. An audit of returned pills and compliance diaries, and weekly blood samples for presence (or absence) of resveratrol were performed. (Supplementary Material)
Dose calculation
The dose of 3000mg was calculated using the body surface area (BSA) normalization method as previously described. 32 The highest dosage used in pre-clinical diet-induced hepatic steatosis (400mg/kg in mice), 19 and the reported highest no observed adverse effect level at the time of protocol development (300mg in rats) 33 were converted to determine a human equivalent dose (HED). Obesity factor calculations were performed, as per U.S. Food and Drug Administration guidance for industry for estimating the maximum safe starting dose for therapeutics. 34 In light of a recent clinical report on administration of 4000mg resveratrol daily over 2 weeks 35 with no toxicity observed, it was deemed unnecessary to apply a safety factor to the HED, as commonly applied for first time administration in humans. 34 
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Euglycemic-hyperinsulinemic clamp
Insulin sensitivity was assessed by the euglycemic-hyperinsulinemic clamp (EHC), 36 as per protocol previously described; 37 the homeostatic model assessment of insulin resistance (HOMA-IR) 38 and the adipose tissue insulin resistance index (AT-IR) 39 were calculated. (Supplementary Material)
Indirect calorimetry
Resting energy expenditure (REE) and fat-oxidation were assessed by indirect calorimetry (TrueOne 2400 Metabolic Measurement System, Parvo Medics, UT), performed in the fasted and insulin stimulated states as previously described. 37
Magnetic resonance imaging and spectroscopy
Magnetic resonance data was acquired on a 3T Siemens TRIO (Erlangen, Germany), as per
protocol. (Supplementary Material)
Plasma biochemistry
Weekly liver and kidney function markers, and all plasma biochemistry assays are outlined in the Supplementary Material.
Pharmacokinetics
A 6-hour pharmacokinetics study was performed. Sampling and UPLC tandem mass-spectrometry protocols are provided in the Supplementary Material.
Peripheral blood mononuclear cells (PBMC) isolation
PBMC purification was performed at baseline, week 1 and week 8 as previously described. 40 
(Supplementary Material)
Target genes transcription
RNA levels of PTP-1B, HO-1, NQO1, and IL-6 were measured by quantitative reverse transcriptase polymerase chain reaction in PBMC of subjects receiving resveratrol as previously described. 41 (Supplementary Material)
Statistical analyses
The study was powered to detect 25% change (80% power and p<0.05) in the primary outcome (glucose disposal rate as a measure of insulin resistance). Eight participants were required in each arm. To account for a possible 25% drop-out in participation, 10 participants were recruited per arm.
Power calculations were based on the reproducibility of the EHC reported in patients with NAFLD. 42 All data was analyzed with intention to treat. Where data was missing, the previous time-point value was brought forward. All analyses were performed on Prism GraphPad Version 6.0c and SPSS Table 1 outlines baseline characteristics and indicates overall homogeneity between the resveratrol and placebo groups.
RESULTS
Baseline characteristics
Compliance Figure 1 presents the study consort flow diagram. All participants completed the 8-week intervention, 85% of participants completed all study investigations. A compliance audit of returned capsules indicated 90% compliance in the resveratrol group, and 75% in the placebo group (data not shown). 
Insulin resistance and target genes expression
At baseline, all participants had profound insulin resistance. Resveratrol treatment did not induce improvement in insulin mediated glucose uptake (Table 2, Figure 2A ). Fasting glucose, insulin, nonesterified fatty acids (NEFA) and AT-IR did not change with treatment (Table 2, Figure 2B ).
Resveratrol led to a statistically significant less effective insulin-mediated suppression of plasma NEFA, however not considered clinically significant (Table 2, Figure 2C ). Total and high-molecular weight (HMW) adiponectin did not change, however the HMW to total adiponectin ratio decreased significantly with resveratrol ( 
Hepatic triglyceride content, abdominal adipose tissue distribution and resting energy expenditure
Resveratrol did not induce change in hepatic steatosis, total abdominal fat or distribution ( Table 2 , Figure 2E and 2F). REE and fasting fat-oxidation remained unchanged ( Table 2) .
Plasma lipids, antioxidant, and inflammation markers
No change was observed in plasma lipids or antioxidant activity with resveratrol. There was a significant increase in IL-10 and decrease in IL-6, but no change in TNFα, IL-1β, IL-8 or C-reactive protein. (Table 2 
, Figures 3C, 3D)
Resveratrol pharmacokinetics
The C max for parent resveratrol was 65.7±35.9ng/mL (0.29uM) at 60 minutes post-ingestion of 1500mg resveratrol in fasted state. The coefficient of inter-individual variation (CV) was 54%. The Previous reports have discussed the potential for drug bioavailability interactions, secondary to inhibition of the phase I drug metabolism enzyme CYP3A4 by resveratrol. 43 No symptom attributed to drug metabolism was observed, and usual medication prescriptions remained unchanged.
Alanine and aspartate aminotransferases (ALT, AST) increased significantly to week 6 (56% and 50% median increase respectively) in the resveratrol group (Table 2 , paired t-test). Statistical significance was not sustained when overall change across the study was assessed by ANOVA ( Figures 5A and 5B ). Cytokeratin 18 (CK-18) fragments and high-mobility-group box-1 (HMGB-1) levels did not change with treatment ( Table 2 ). Serum creatinine and potassium concentration did not change (Table 2) .
Other parameters
Other variables measured included: IGF-1 and IGFBP-3, F2-isoprostanes, blood pressure, vitamin C ( Table 2) ; none changed with resveratrol.
DISCUSSION
Daily 3000mg resveratrol treatment did not induce therapeutic benefits in men with established NAFLD.
Resveratrol did not improve typical characteristics of NAFLD
Insulin resistance
Fasting glucose, insulin, and the M value did not change. The M/I index, or the quantity of glucose disposed per unit of insulin concentration during the EHC (clinically most representative of the degree of IR) did not change ( Table 2 ). The lack of effect of resveratrol on insulin sensitivity has been previously reported in overweight or obese healthy subjects at various resveratrol dosages (daily 75mg to 1500mg) using similar gold-standard protocols to assess functional IR. 29, 31 In contrast, in populations with type 2 diabetes, the adjunction of resveratrol to standard care showed significant improvement in mechanisms of glucose control, and reduced oxidative stress across a M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 11 range of daily doses (10mg daily 26 , 250mg 44 , or 1000mg 45 ). These studies suggest that the severity of metabolic dysregulation prior to resveratrol treatment, and the combination with pharmacological agents that target AMP-kinase activation, could be of importance for measurable benefits of resveratrol. 46, 47 PTP-1B, a negative regulator of insulin signaling, was shown significantly repressed in PBMC of healthy humans receiving 40mg resveratrol daily for 6 weeks, 28 and suggested as another mechanism for improved insulin sensitivity by resveratrol. 48 PTP-1B transcription remained however unchanged in the present study, consistent with the no improvement in IR. Total and HMW adiponectin did not change, also consistent with no effect on IR. This contradicts a recent clinical report of increased circulating adiponectin by 9.6% after 1 year of daily 8mg resveratrol in combination with grape extract in a population with cardiovascular disease. 49 These overall discrepant results indicate that dose-finding studies including a dose-spectrum from dietary to pharmacological, are required. 47
Hepatic and abdominal fat distribution
Hepatic steatosis, abdominal adipose tissue distribution and weight remained unchanged, implying that resveratrol did not promote fat-oxidation. Indirect calorimetry results for REE and fat-oxidation confirmed this. Significant reduction in hepatic fat with resveratrol was previously reported in obese healthy subjects, 30 but this was observed within the clinically normal range of less than 5% steatosis, which may reflect day to day variability and not predict improvement in pathological fat accumulation, characteristic of NAFLD. 50 The subjects in the present study had up to 54% steatosis measured by MRS. The mechanism of resveratrol on lipid metabolism has been proposed via activation of AMPK, SIRT1, and the resulting increased fat-oxidation. 51 The lipolytic activity of resveratrol has also been reported in human adipocytes via regulation of adipose triglyceride lipase. 52 Increased lipolytic activity present as an advantage, whereby more fatty acids become available substrate for muscles.
However in the context of reduced hepatic and whole body fat-oxidation ability as has been recently reported in NAFLD patients, 37 
Inflammation and antioxidant activity
The observed increase in IL-10 and decrease in IL-6 suggest a modest improvement in the circulating inflammatory profile with resveratrol. However mRNA level of IL-6 in PBMC did not change. NQO1 mRNA levels appeared to decrease significantly between week 1 and week 8, suggesting different acute and long-term effects. However, the repeated-measures ANOVA indicated no significant change across time-points. The pre-clinical evidence of the effect of resveratrol on regulators of inflammation and on the endogenous antioxidant defense is abundant. 47 The clinical evidence is however mixed, likely explained by the baseline health status of subjects, dosage variety, and fasting or post meal-challenge sampling protocols, which assess different outcomes. [28] [29] [30] [31] 53 
Safety and plasma resveratrol concentration
A rise in ALT and AST is generally attributed to hepatocyte injury, however plasma CK-18 and HMGB-1 concentrations did not increase significantly (Table 2 ), suggesting there was little hepatocyte necrosis. The repeated-measures ANOVA failed to find statistical significance across the study, and ALT and AST concentrations appeared to fall after week 6. The significant rise up to week 6 is nevertheless concerning, especially since the long-term effects of resveratrol supplementation were not investigated in this study. Moreover, resveratrol is advertised as a calorierestriction mimic targeting populations likely to present with obesity related co-morbidities such as NAFLD. This warrants adequate warning and further research. The 3000mg daily dose was chosen after consideration of the lipophilic characteristics of resveratrol, and assumed altered pharmacokinetics in obesity with increased fat-mass. 54, 55 The split-dosing regimen was aimed at increasing exposure to circulating parent compound despite known extensive metabolism. The mean C max and AUC 0-24 were however 52% and 41% lower respectively after 1500mg resveratrol (Figure 4) , than the C max and AUC 0-24 after 1000mg in healthy subjects previously reported. 56 It is nonetheless difficult to compare the concentration of parent resveratrol in the present study with
other clinical data, because of variable analytical methods employed. Methods measure total resveratrol including metabolites, 35 or use enzymatic hydrolysis to reconvert metabolites to parent compound prior to analysis. 30, 31 From our data, it could be speculated that resveratrol kinetics may be altered in obesity with chronic liver disease, resulting in reduced parent concentration. It could also be speculated that the chronic high-dose may have resulted in saturation at absorption sites as seen with high-dose lipophilic nutrients when taken out of the food matrix, 57 or with micronutrient absorption interactions. 58
What defines a therapeutic dose?
This is to our knowledge the first study administering the pharmacological dose of 3000mg daily for 8 weeks to an obese cohort with chronic liver disease. It is unclear what animal dose should be selected as benchmark for therapeutic HED calculations. Broad dosages have been used preclinically (from 1mg to 750mg/kg of body weight, or food consumed by animals) without pharmacokinetics data provided, or described rationale for dose selection. When converted through the BSA normalization method, 32 the dose received by the participants in the present study equated approximately to that received by mice in the investigation of resveratrol in the prevention of dietinduced obesity complications. 19 There is no agreed consensus on the best method to calculate a HED for bioactive food-constituents considering allometric scaling. 59 Dose-calculation limitations further exist for an obese population with concurrent co-morbidities. Standards for BSA, absorption, metabolism and body-composition often rely on assumed data from 60kg adults, 34 and do not take into consideration obesity-related changes leading to altered drug distribution and clearance. 60 Pharmacokinetic monitoring and chemotherapy dosing adjusted to weight is well documented. 61 Body composition studies in the obese suggest that drug clearance is not proportional to total body weight, but correlates more accurately with lean body mass (LBM). 60 Chronic dosing depends on drug clearance, as the aim is to achieve a steady state concentration related to efficacy. 54 Therefore animal dosage conversion to HED based on LBM may be more adequate for nutraceuticals targeted for chronic disease therapy.
Furthermore, the distinction between prevention and therapy is rarely addressed in pre-clinical studies, the prevention models being most commonly employed to determine the therapeutic potential of an agent. Chronic disease develops over time however, and treatment may consequently involve vastly different pathways than those for prevention.
The poor bioavailability of resveratrol is perhaps a protective mechanism
The extensive conjugation of resveratrol may indicate a protective mechanism against highconcentration of parent compound from bolus nutraceutical doses. 62 Clinical evidence of resveratrol accumulation in colorectal tissue 63 has confirmed early animal evidence, and likely predicts accumulation in other tissues. 64 Sulfate metabolites were reported undergoing hydrolysis back to parent compound intra-cellularly, thus suggested to constitute a "sustained release" pool of parent compound. 65, 66 Resveratrol conjugates have also been reported to hold bioactivity potential. 67, 68 Therefore, circulating concentrations of parent-resveratrol at a given time-point is not representative of actual exposure, and is potentially an incorrect target for expected efficacy.
The lack of therapeutic effect in the present study questions the dose adequacy, and the efficacy of resveratrol in humans with hepatic steatosis. A lack of effect at larger doses was previously reported when markers of efficacy on the IGF-1 axis did not increase proportionally with dose in healthy volunteers. 56 Resveratrol has been shown to have hormetic effects in cell and animal models for a range of disease states, with protective effects at low dose but adverse effects at higher doses. 62, 69 However it is not clear if, and at what dose, this change occurs in humans. Further, it is unclear whether a nutraceutical dose would qualify as a "large" dose physiologically, regardless of size, due to its bolus delivery, compared to a dietary source. 47 Dose-comparison studies are needed to determine differential dose-dependent effects.
CONCLUSION
The present study demonstrates that the preventive role of resveratrol observed in diet-induced preclinical models of NAFLD does not translate into a therapeutic role in clinical established NAFLD.
We provide evidence that in obese subjects with chronic fatty liver disease, 8 weeks 
LIMITATIONS
This study was powered to detect 25% change in glucose disposal rate during the EHC. There is potential for type 2 errors in all other variables. The EHC protocol did not include glucose tracers, and thus did not allow for distinction between specific sites of insulin resistance. The MRS method was unable to determine severity of liver disease or changes to hepatic fibrosis and inflammation.
The study involved exclusively male participants. The pharmacokinetics protocol was included to monitor presence of parent resveratrol during the study, and dosage kinetics. As resveratrol metabolites were not measured, actual exposure to resveratrol species cannot be determined. 
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Inflammation and oxidative stress
Plasma antioxidant activity Ferric reducing ability of plasma (µmol/L)
HDL (mmol/L)
1.0 (0.9 -1.1) 1.0 (0.9 -1.1) 0.7 0.9 (0.8-0.9) 0.9 (0.7-1.1) 0.9
LDL (mmol/L)
3.2 ± 0.7 3.5 ± 0.9 0.07 2.8 ± 0.8 2.7 ± 0.9 0.08 Participants were provided with a compliance diary to be filled daily, and were asked verbally about compliance to prescribed capsule intake at the weekly reviews. Figure 1 shows the concentration of parent resveratrol measured at the weekly reviews. 
Abdominal adipose tissue distribution
IGF-1 axis Insulin-like growth factor (IGF) 1 (ng/mL)
67±26 61±22 0.2 60±23 69±28 0.07
IGF-binding-protein 3 (ng/mL)
4120±1063 4113±1239 0.9 4852±1215 4826±1418 0.8
Resveratrol group only target genes transcription in peripheral blood mononuclear cells (n=9)
Genes
Paired test for change in RNA levels at time points
Analysis of variance in multiple time points
Magnetic resonance imaging and spectroscopy (MRI and MRS)
All magnetic resonance data were acquired on a 3T Siemens TRIO (Erlangen, Germany). Following liver MRI and MRS, the patient's bed was moved to position L4 at the gradient isocentre. Dixon images, as described for the liver, were centred on the L4 and acquired. Ferric reducing ability of plasma (FRAP) was measured using the method as per. 8 Plasma was incubated with freshly prepared FRAP reagent and absorbance was measured spectrophotometrically (Cobas Mira, Roche Diagnostics, Australia).
Superoxide dismutase (SOD) was measured spectrophotometrically (FLUOstar Optima, BMG Labtech, Germany) using a kit and standards by Cayman Chemical (MI, USA). 
